TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
9.60
+0.27 (2.89%)
At close: Mar 6, 2026, 4:00 PM EST
9.59
-0.01 (-0.10%)
After-hours: Mar 6, 2026, 6:11 PM EST
TransCode Therapeutics Employees
TransCode Therapeutics had 7 employees as of December 31, 2024. The number of employees decreased by 3 or -30.00% compared to the previous year.
Employees
7
Change (1Y)
-3
Growth (1Y)
-30.00%
Revenue / Employee
n/a
Profits / Employee
-$3,876,275
Market Cap
8.80M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 57 |
| Bolt Biotherapeutics | 40 |
| KALA BIO | 38 |
| NuCana | 22 |
| SeaStar Medical Holding | 19 |
| Cardio Diagnostics Holdings | 15 |
| BioVie | 13 |
| Iterum Therapeutics | 9 |
RNAZ News
- 4 days ago - TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients - PRNewsWire
- 12 days ago - TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development - PRNewsWire
- 4 weeks ago - TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 - PRNewsWire
- 2 months ago - TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma - PRNewsWire
- 2 months ago - TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors - PRNewsWire
- 3 months ago - TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial - PRNewsWire
- 3 months ago - TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer - PRNewsWire
- 5 months ago - TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO - PRNewsWire